Literature DB >> 15554783

The role of dopamine in obsessive-compulsive disorder: preclinical and clinical evidence.

Damiaan Denys1, Joseph Zohar, Herman G M Westenberg.   

Abstract

Obsessive-compulsive disorder (OCD) is a frequent and chronic psychiatric disorder that has been linked closely to the serotonin system mainly because of the antiobsessional efficacy of selective serotonin reuptake inhibitors (SSRIs). A limitation of the serotonin hypothesis of OCD is that a substantial number of the patients with OCD show no significant improvement after an adequate trial with SSRIs. There is substantial evidence that these patients may benefit from addition of antipsychotics to their ongoing SSRI treatment, suggesting that dopamine also might play a role in the pathophysiology of OCD. In this review, the preclinical and clinical evidence on the role of dopamine in OCD is summarized.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15554783

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  65 in total

1.  Basal ganglia MR relaxometry in obsessive-compulsive disorder: T2 depends upon age of symptom onset.

Authors:  Stephen Correia; Emily Hubbard; Jason Hassenstab; Agustin Yip; Josef Vymazal; Vit Herynek; Jay Giedd; Dennis L Murphy; Benjamin D Greenberg
Journal:  Brain Imaging Behav       Date:  2009-12-12       Impact factor: 3.978

2.  Aripiprazole augmentation in treatment-refractory obsessive-compulsive disorder.

Authors:  Rahul Sarkar; Julia Klein; Stephanie Krüger
Journal:  Psychopharmacology (Berl)       Date:  2008-02-10       Impact factor: 4.530

Review 3.  Obsessive-compulsive disorder: Insights from animal models.

Authors:  Henry Szechtman; Susanne E Ahmari; Richard J Beninger; David Eilam; Brian H Harvey; Henriette Edemann-Callesen; Christine Winter
Journal:  Neurosci Biobehav Rev       Date:  2016-05-07       Impact factor: 8.989

Review 4.  A compensatory role for declarative memory in neurodevelopmental disorders.

Authors:  Michael T Ullman; Mariel Y Pullman
Journal:  Neurosci Biobehav Rev       Date:  2015-01-15       Impact factor: 8.989

Review 5.  Peromyscus maniculatus bairdii as a naturalistic mammalian model of obsessive-compulsive disorder: current status and future challenges.

Authors:  De Wet Wolmarans; Isabella M Scheepers; Dan J Stein; Brian H Harvey
Journal:  Metab Brain Dis       Date:  2017-12-06       Impact factor: 3.584

6.  [123I] ADAM brainstem binding correlates with the loudness dependence of auditory evoked potentials.

Authors:  Oliver Pogarell; Walter Koch; Nadine Schaaff; Gabriele Pöpperl; Christoph Mulert; Georg Juckel; Hans-Jürgen Möller; Ulrich Hegerl; Klaus Tatsch
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-11-07       Impact factor: 5.270

7.  Toxoplasma gondii infection, from predation to schizophrenia: can animal behaviour help us understand human behaviour?

Authors:  Joanne P Webster; Maya Kaushik; Greg C Bristow; Glenn A McConkey
Journal:  J Exp Biol       Date:  2013-01-01       Impact factor: 3.312

8.  Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.

Authors:  Stefano Pallanti; Silvia Bernardi; Sarah Antonini; Nikhilesh Singh; Eric Hollander
Journal:  CNS Drugs       Date:  2009-12       Impact factor: 5.749

9.  The role of the striatum in compulsive behavior in intact and orbitofrontal-cortex-lesioned rats: possible involvement of the serotonergic system.

Authors:  Eduardo A Schilman; Oded Klavir; Christine Winter; Reinhard Sohr; Daphna Joel
Journal:  Neuropsychopharmacology       Date:  2010-01-13       Impact factor: 7.853

Review 10.  Probing compulsive and impulsive behaviors, from animal models to endophenotypes: a narrative review.

Authors:  Naomi A Fineberg; Marc N Potenza; Samuel R Chamberlain; Heather A Berlin; Lara Menzies; Antoine Bechara; Barbara J Sahakian; Trevor W Robbins; Edward T Bullmore; Eric Hollander
Journal:  Neuropsychopharmacology       Date:  2009-11-25       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.